Similar to the previous blog post covering the AABB abstracts from the Vancouver General Hospital study, this post will cover an abstract generated by a hospital that has recently evaluated ThromboLUX.
This time we are looking at the work done by Dr. Inga Gurrevich, Brant Keener, and Dr. Joel Kniep at the University of Colorado Hospital. The data set was generated during a recently completed quality initiative at the Hospital which investigated the impact of platelet activation status-based inventory management on the platelet utilization of hematology-oncology patients.
Their AABB abstract investigated whether pathogen reduction changed the activation status of single donor platelets. The abstract will be presented orally on Saturday, October 13th at 2:15 pm during the Components Abstract Session. For more details on the session click here.
Abstract ID TS16-ST4-25:
Activation Status of Pathogen Reduced Platelet Components in Plasma in Comparison with Conventional Plasma Platelet Components
Studies suggest that high microparticle (MP) content (activated) platelets may be beneficial to stop active bleeding. Conversely, platelet components with a low MP content (non-activated) may be beneficial for prophylactic platelet transfusion, especially in bone marrow transplant patients.
In this abstract, Dr. Gurrevich et al. discuss the possibility that pathogen reduction technology (PRT) impacts the activation status of platelet units. During the study, they received both PRT and conventional (non-PRT) platelets from their regional blood supplier. They tested the MP content of each platelet unit using ThromboLUX.
Using the standard 15% microparticle threshold to differentiate non-activated platelets and activated platelets suspended in plasma they found 34.7% of PRT and 34.1% of non-PRT platelets to be activated. Statistical analysis found no significant difference between the two component types thus they concluded that PRT and non-PRT platelets showed similar platelet activation distributions in their study.
For additional details on this study please attend abstract session ST4-25 in room 253C of the Boston Convention and Exhibition Center on Saturday, October 13th. This abstract is scheduled to be presented at 2:15 pm.
AABB Industry Workshop
You can hear additional results from the quality initiative conducted at the University of Colorado Hospital along with three other ThromboLUX studies by attending our workshop at AABB the morning of October 15th or by visiting us in the exhibit hall at Booth 724.